文献速递神经肿瘤

多原发肿瘤背景下成人恶性胶质瘤的管理与生存趋势:一项基于人群的分析

Management and survival trends for adult patients with malignant gliomas in the setting of multiple primary tumors: a population based analysis.
PubMed 文献 · J Neurooncol · 2018-11-05

该研究从SEER-18登记库提取成人恶性胶质瘤患者数据,按恶性胶质瘤相对于其他原发肿瘤的诊断顺序分为A组(仅一个原发或第一原发)和B组(第二或后续原发)。B组占新发恶性胶质瘤的12.8%,发病率范围为0.14至0.18。与A组相比,B组年龄更大,女性、白人、较小肿瘤、未手术及接受放疗的比例更高(p < 0.05),全切除比例相当;多个分组(口腔、消化系统、呼吸系统、皮肤、乳腺、生殖系统、泌尿系统、淋巴瘤)的胶质瘤相关观察生存低于A组(p < 0.05)。结论认为,新诊断恶性胶质瘤中高比例患者有中枢神经系统外原发肿瘤史,这些患者的胶质瘤相关观察生存通常更差,了解其流行病学、临床因素和观察生存有助于指导临床管理/咨询。

要点

  • B组(第二或后续原发)占新发恶性胶质瘤的12.8%,发病率范围为0.14至0.18。
  • B组较A组年龄更大,女性、白人、较小肿瘤、未手术及接受放疗比例更高(p < 0.05)。
  • 多个原发肿瘤分组(口腔、消化、呼吸、皮肤、乳腺、生殖、泌尿、淋巴瘤)的胶质瘤相关观察生存低于A组(p < 0.05)。

核心结论

  • 新诊断恶性胶质瘤中高比例患者有中枢神经系统外原发肿瘤史,这些患者的胶质瘤相关观察生存通常较仅一个原发或第一原发的患者更差。
  • 了解该亚组患者的流行病学、临床因素和观察生存有助于指导临床管理/咨询。

研究设计与样本

  • 从SEER-18登记库提取成人恶性胶质瘤患者的人口学和临床数据。
  • 按恶性胶质瘤相对于其他原发肿瘤的诊断顺序分组:A组为仅一个原发或第一原发,B组为第二或后续原发。
  • 分析发病率、频率和胶质瘤相关生存。

主要发现

  • B组占新发恶性胶质瘤的12.8%,其发病率相对于所有新发恶性胶质瘤的范围为0.14至0.18。
  • 与A组相比,B组年龄更大,女性、白人、较小肿瘤、未手术及接受放疗的比例更高(p < 0.05),全切除比例相当。
  • 多个分组(口腔、消化系统、呼吸系统、皮肤、乳腺、生殖系统、泌尿系统、淋巴瘤)的胶质瘤相关观察生存低于A组(p < 0.05)。
  • 活动性诊断「白血病」似乎赋予更长的胶质瘤相关生存,而「乳腺」或「消化系统」恶性肿瘤病史则预示更短的胶质瘤相关生存。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: The impact of multiple primary tumors, in the setting of malignant glioma (MG), has not been heavily explored. METHODS: We extracted demographics and clinical data from the SEER-18 registry for adult patients with MGs. The cases were separated based on the sequence of MG diagnosis relative to the other primary tumors: Group (A) One primary only or first primary of multiple primaries and Group (B) second primary or subsequent primary tumor. Incidences, frequencies, and glioma-related survivals were analyzed. RESULTS: Group B constituted 12.8% of new MG. The incidences of group B, relative to those of all new MG, range from 0.14 to 0.18. Compared to group A, group B exhibited an older age. Moreover, group B exhibited a higher proportion of females, Caucasians, smaller tumors, non-operative cases, and those receiving radiation (p < 0.05); the proportion with GTR remained comparable. Multiple groupings (oral cavity, digestive system, respiratory system, skin, breast, genital systems, urinary system, lymphoma) exhibited lower glioma-related observed survival (p < 0.05) compared to Group A. An active diagnosis of "leukemia" appears to confer longer glioma-related survival while a history of "breast" or "digestive system" malignancies portends a shorter glioma-related survival. CONCLUSION: For newly diagnosed MG, a high proportion does have history of extra-CNS primary tumors. Generally, these patients appear to have worse glioma-related observed survival compare to those with malignant glioma as the only primary or the first of multiple primary tumors. Knowledge regarding epidemiology, clinical factors, and observed survival can help guide clinical management/consultation for this subset of patients.

来源:J Neurooncol,查看原文。版权归原作者所有。

引用

  1. Nguyen HS, Doan NB, Gelsomino M, et al. Management and survival trends for adult patients with malignant gliomas in the setting of multiple primary tumors: a population based analysis. J Neurooncol. 2018. PMID: 30397742. doi:10.1007/s11060-018-03028-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。